BMRN vs. ALNY, BIIB, UTHR, NBIX, INCY, EXAS, EXEL, RGEN, HALO, and MDGL
Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry.
BioMarin Pharmaceutical vs.
BioMarin Pharmaceutical (NASDAQ:BMRN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk.
BioMarin Pharmaceutical has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.
BioMarin Pharmaceutical has a net margin of 11.71% compared to Alnylam Pharmaceuticals' net margin of -15.86%. BioMarin Pharmaceutical's return on equity of 8.53% beat Alnylam Pharmaceuticals' return on equity.
BioMarin Pharmaceutical has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Alnylam Pharmaceuticals had 7 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 31 mentions for Alnylam Pharmaceuticals and 24 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.79 beat Alnylam Pharmaceuticals' score of 0.70 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.
BioMarin Pharmaceutical received 428 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 74.54% of users gave BioMarin Pharmaceutical an outperform vote.
BioMarin Pharmaceutical presently has a consensus price target of $94.20, suggesting a potential upside of 53.10%. Alnylam Pharmaceuticals has a consensus price target of $298.61, suggesting a potential upside of 21.25%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, equities research analysts clearly believe BioMarin Pharmaceutical is more favorable than Alnylam Pharmaceuticals.
98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 1.9% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
BioMarin Pharmaceutical beats Alnylam Pharmaceuticals on 14 of the 19 factors compared between the two stocks.
Get BioMarin Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioMarin Pharmaceutical Competitors List
Related Companies and Tools
This page (NASDAQ:BMRN) was last updated on 1/20/2025 by MarketBeat.com Staff
